Previous close | 37.35 |
Open | 42.50 |
Bid | 29.56 x 200 |
Ask | 35.82 x 100 |
Day's range | 34.68 - 42.50 |
52-week range | 12.57 - 42.50 |
Volume | |
Avg. volume | 696,740 |
Market cap | 1.351B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript May 8, 2024 Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Tarsus’s First Quarter 2024 Financial Results Conference Call. As a reminder, this […]
Explore key financial outcomes and strategic insights from Tarsus Pharmaceuticals' first quarter of 2024, highlighting significant sales growth and market penetration efforts.
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?